title: A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer.
abstract: Stereotactic ablative body radiotherapy (SABR) describes a radiotherapy (RT) technique where high doses of radiation are precisely delivered to an extracranial target within the body, using either a single fraction of RT or using multiple small numbers of fractions. SABR has now become the standard of care treatment for patients with early-stage non-small-cell lung cancer (NSCLC) for whom surgery is not appropriate. This systematic review considers the evidence supporting the use of SABR in early-stage NSCLC, reported toxicity rates, the use of SABR in centrally located NSCLC, the use of SABR as salvage therapy following surgery or RT, and future potential drug combinations with SABR.
authors.affiliation: 1 Leeds Cancer Centre, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
authors.forename: Patrick
authors.identifier: http://orcid.org/0000-0002-5367-5103
authors.initials: P
authors.lastname: Murray
authors.affiliation: 1 Leeds Cancer Centre, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
authors.forename: Kevin
authors.initials: K
authors.lastname: Franks
authors.affiliation: 2 Centre for Cancer Research and Cell Biology, Queen's University of Belfast, Belfast, Northern Ireland, UK.
authors.forename: Gerard G
authors.initials: GG
authors.lastname: Hanna
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000532:radiotherapy*; D006801:Humans; D008175:Lung Neoplasms / Q000532:radiotherapy*; D016634:Radiosurgery / Q000379:methods*; D016896:Treatment Outcome